|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59.5 EUR | +0.37% |
|
+3.05% | +1.40% |
| May. 02 | DANONE : UBS keeps its Buy rating | ZD |
| May. 02 | Danone: acquisition of Functional Formularies | CF |
| Entry price | Target | Stop-loss | Potential |
|---|---|---|---|
| €75 | €78 | €73.1 | +4% |
● In a short-term perspective, the company has interesting fundamentals.
● Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
● The group shows a rather high level of debt in proportion to its EBITDA.
| 1st Jan change | Capi. | |
|---|---|---|
| +1.40% | 41.13B | |
| -2.39% | 275B | |
| -1.70% | 95.5B | |
| -2.00% | 44.01B | |
| +9.84% | 41.41B | |
| +8.54% | 39.91B | |
| -12.79% | 31.14B | |
| -4.77% | 29.23B | |
| +14.15% | 25.26B | |
| -4.34% | 23.96B |
DANONE 
